Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …
cancer characterized by unbridled proliferation of malignant marrow stem cells with …
Recent advances in targeted therapies in acute myeloid leukemia
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …
for younger patients over the last several decades has improved nearly sixfold with the …
A review of FLT3 inhibitors in acute myeloid leukemia
JC Zhao, S Agarwal, H Ahmad, K Amin, JP Bewersdorf… - Blood reviews, 2022 - Elsevier
FLT3 mutations are the most common genetic aberrations found in acute myeloid leukemia
(AML) and associated with poor prognosis. Since the discovery of FLT3 mutations and their …
(AML) and associated with poor prognosis. Since the discovery of FLT3 mutations and their …
Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review
X Zou, XY Tang, ZY Qu, ZW Sun, CF Ji, YJ Li… - International Journal of …, 2022 - Elsevier
Platelet-derived growth factors (PDGFs) and PDGF receptors (PDGFRs) are expressed in a
variety of tumors. Activation of the PDGF/PDGFR signaling pathway is associated with …
variety of tumors. Activation of the PDGF/PDGFR signaling pathway is associated with …
Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes
PURPOSE Outcomes are poor in TP53-mutant (m TP53) acute myeloid leukemia (AML) and
myelodysplastic syndromes (MDS), even after allogeneic hematopoietic stem-cell transplant …
myelodysplastic syndromes (MDS), even after allogeneic hematopoietic stem-cell transplant …
[HTML][HTML] The clinical impact of the molecular landscape of acute myeloid leukemia
S Kayser, MJ Levis - Haematologica, 2023 - ncbi.nlm.nih.gov
Research into the underlying pathogenic mechanisms of acute myeloid leukemia (AML) has
led to remarkable advances in our understanding of the disease. Mutations now allow us to …
led to remarkable advances in our understanding of the disease. Mutations now allow us to …
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open …
L Xuan, Y Wang, K Yang, R Shao, F Huang… - The Lancet …, 2023 - thelancet.com
Background Our open-label, multicentre, randomised, phase 3 trial showed that sorafenib
maintenance after haematopoietic stem-cell transplantation (HSCT) improved overall …
maintenance after haematopoietic stem-cell transplantation (HSCT) improved overall …
Allogeneic stem cell transplantation for acute myeloid leukemia: who, when, and how?
Although the majority of patients with acute myeloid leukemia (AML) treated with intensive
chemotherapy achieve a complete remission (CR), many are destined to relapse if treated …
chemotherapy achieve a complete remission (CR), many are destined to relapse if treated …
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial
RA Larson, SJ Mandrekar, LJ Huebner, BL Sanford… - Leukemia, 2021 - nature.com
The prospective randomized, placebo-controlled CALGB 10603/RATIFY trial (Alliance)
demonstrated a statistically significant overall survival benefit from the addition of …
demonstrated a statistically significant overall survival benefit from the addition of …
How I treat AML incorporating the updated classifications and guidelines
F El Chaer, CS Hourigan… - Blood, The Journal of the …, 2023 - ashpublications.org
Abstract The European LeukemiaNet recently revised both the clinical (2022) and
measurable residual disease testing (2021) guidelines for acute myeloid leukemia (AML) …
measurable residual disease testing (2021) guidelines for acute myeloid leukemia (AML) …